Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Urolect
- Development stage
- Unknown
- Lead developer
- Spey Medical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Urolect is an oral effervescent urinary and systemic alkalinizer containing a combination of sodium bicarbonate, citric acid, sodium citrate, and tartaric acid. It is indicated for urinary alkalinization to relieve dysuria associated with urinary tract infections, to enhance the efficacy of certain antibiotics, and to prevent or treat uric acid, cystine, and calcium oxalate kidney stones. It is also used for gastric alkalinization to treat gastric hyperacidity. Urolect is developed by SPEY and manufactured by Ind-Swift.
- Brand names
- Urolect
- Other names
- citric acid + sodium bicarbonate + sodium citrate + tartaric acid
Beyond the preview
Go deeper on Urolect.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Urolect.